BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:18 PM
 | 
Jun 28, 2010
 |  BC Extra  |  Clinical News

New Avandia data shows lower risk of CV events

A post hoc analysis led by Richard Bach of the Washington University School of Medicine showed diabetes drug Avandia rosiglitazone produced a significantly lower composite rate of death, myocardial infarction (MI) and stroke compared to no thiazolidinedione (TZD) therapy. However, the analysis also showed that the Avandia group had a significantly higher rate of fracture vs. no TZD therapy. The analysis comprised data from...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >